DBV Technologies (DBVT) Q3 2026 earnings review
DBV files its peanut patch application, but cash runs short
DBV Technologies, a French developer of skin patches for food allergies, filed its lead US drug application while its cash outflow accelerated. Chief executive Daniel Tassé submitted the 4-to-7 peanut patch file at the end of September and raised $50 million in July. Even with that fresh cash, third-quarter cash use reached $57 million by our math and left the company with less than 12 months of funding.
| Cash used in Q3 (by our math) | $56.8M $32.7M a year ago |
|---|---|
| Net loss | $64.5M $33.2M a year ago |
| Ending cash | $165.7M after $50M July stock sale |
| Cash runway outlook | Unchanged into Q3 2027 (going-concern warning) |
⚖️ Verdict: 🔴 Bearish
The story got worse because rising launch costs absorbed the July funding without extending the cash runway, and a factory regulatory risk surfaced. Management brought back a formal going-concern warning, delayed the toddler filing to 2027, and disclosed an April FDA Warning Letter at its contract manufacturer, Fareva. On the positive side, filing the 4-to-7 application and reopening the stock-sale programme cleared two near-term hurdles.
The question now is whether the FDA accepts the 4-to-7 patch application for Priority Review and clears the Fareva factory on time. A clean acceptance keeps a 2027 launch on track and helps DBV raise more cash, while a filing refusal or factory delay leaves the company short of funds before approval. The fourth-quarter FDA acceptance decision will give the first read.
🐂 Bull Case
FDA Application Filed for Children Aged 4–7
“The third quarter marked a defining step in DBV’s evolution from a clinical-stage company into a commercial organization.” Chief executive Daniel Tassé backed that claim by filing the Biologics License Application (BLA), a formal request for US approval to sell a biological treatment, for the Viaskin Peanut patch in children aged 4 to 7 on September 29.
The French allergy specialist also asked the Food and Drug Administration (FDA) for Priority Review, which shortens the agency's review clock. Submitting the file meets the third-quarter target management set in June after a formatting delay, so the main regulatory catalyst is now in motion.
What to watch: the FDA decision on whether to accept the file and grant Priority Review in the fourth quarter of 2026. A refusal to file would push potential approval and first sales back by several quarters.
New Stock Sale Reopens the Funding Tap
DBV relies on an at-the-market (ATM) programme, a setup that lets a company sell new shares incrementally to investors, to fund its operations. That funding route closed in April when the underlying registration filing expired.
In July the patch developer refreshed the $150 million programme and sold $50 million in American Depositary Shares (ADSs), its US-traded stock certificates, to healthcare fund RA Capital Management. This removes the freeze on its fastest funding tool and leaves $100 million of capacity by our math.
What to watch: additional share sales or warrant exercises over the next two quarters. Selling the remaining $100 million capacity would cover less than two quarters of cash use at the current pace.
🐻 Bear Case
Cash Outflow Accelerated and Going-Concern Doubt Returned
DBV is hiring sales, medical and administrative staff to prepare for a US launch while still funding clinical trials. Those preparations lifted total operating expenses 79% from a year ago to $66.3 million, and management now states that “substantial doubt exists about the Company’s ability to continue as a going concern within twelve months”.
- Third-quarter cash outflow: $56.8 million by our math, up from $53.6 million in the second quarter
- Research and development: $47.0 million, up 64%, including $4.7 million of FDA filing fees and $4.5 million of early patch inventory
- Sales, marketing and administrative costs: $19.3 million combined, taking 6.2 percentage points more of total operating expenses than a year ago by our math
- Ending cash: $165.7 million on September 30, even after raising $50 million in July
Despite the $50 million stock sale, the cash runway still ends in the third quarter of 2027. Stretching $165.7 million across four quarters requires average cash use of at most $41.4 million per quarter by our math, a 27% cut from the third-quarter rate. The company says its budgets “incorporate milestone-based spending assumptions”, so commercial hiring only slows if the FDA review stalls.
What to watch: fourth-quarter cash use in the full-year report. A figure above $45 million would leave DBV with less than three quarters of cash before any product approval.
Contract Factory Received an FDA Warning Letter
Fareva Amboise (Fareva) is DBV's contract manufacturer responsible for producing the Viaskin Peanut patch for commercial sale. Before the FDA approves a biological product, the agency conducts a Pre-Approval Inspection (PAI), a factory audit to verify manufacturing quality.
The company disclosed that it is working with its partner on repairs “following the April 2026 FDA Warning Letter to Fareva”. DBV included a target inspection date in its application that “falls after the date by which Fareva expects to complete remediation”.
This matters because the biotechnology firm has no backup patch factory. If Fareva misses its repair schedule or fails the inspection, the FDA can withhold approval of the patch regardless of the clinical trial data.
What to watch: confirmation that Fareva has completed its remediation work ahead of the FDA factory inspection. Any delay in factory repairs would stall the 4-to-7 approval timeline.
Toddler Application Pushed Out to 2027
DBV is also developing the Viaskin Peanut patch for toddlers aged 1 to 3, a larger patient group that followed the 4-to-7 programme. Management previously planned to submit that second FDA application in the second half of 2026.
After speaking with regulators, the French drugmaker now expects to submit the toddler application in 2027, including a “potential rolling submission of the 1-through-3 BLA”. The same FDA team will review both age groups and wants to apply lessons from the 4-to-7 file to the toddler submission.
What to watch: the finalized submission schedule once FDA discussions conclude. A late-2027 filing would push toddler commercial sales into 2028 or 2029.
Risks this quarter didn't answer
Three standing concerns received no update in the third-quarter release.
- COMFORT Toddlers safety study results: recruitment closed in the second quarter, and topline safety data are still needed to support the toddler filing.
- Commercial pricing and payer terms: DBV is selecting specialty pharmacies and distributors, and has not shared expected patch pricing or reimbursement terms.
- Euro cost exposure: the press release omitted the cash flow statement, leaving the third-quarter foreign-exchange impact on its euro-heavy cost base unreadable until the quarterly filing.
💲 Other KPIs
Up 233% from a year ago by our math. Because DBV issued stock and investors exercised warrants over the past year, net loss per share shrank 42% to $0.14 even though total net loss nearly doubled to $64.5 million.
Down 43% from $2.8 million a year ago. DBV has no approved products, so its operating income line consists entirely of French research tax credits, which shrink as spending moves from clinical trials to US launch preparation.
🔮 Guidance
Unchanged. Existing cash of $165.7 million still funds the company into the third quarter of 2027, less than 12 months from the October report date. By our math, that plan leaves at most $41.4 million of average quarterly cash use over the next four quarters, down from $56.8 million in Q3. Management has only maintained its runway horizon in past quarters by raising fresh equity.
Pushed out. The company now plans to submit the toddler FDA application in 2027 rather than the second half of 2026. Regulators indicated that starting the toddler review shortly after the 4-to-7 review allows the same FDA team to use overlapping data from the older children's filing.
New. Management expects the FDA to decide in the fourth quarter of 2026 whether the 4-to-7 application is complete enough for a full review and whether to grant Priority Review.
❓ Key Questions
What triggered the April FDA Warning Letter at Fareva?
DBV disclosed that its contract manufacturer received a Warning Letter in April 2026. Investors need to know whether the cited deficiencies touch the Viaskin patch lines and when Fareva expects to finish its repairs.
Why has DBV not released COMFORT Toddlers safety data?
Recruitment for the toddler supplemental safety study closed in the second quarter of 2026, and the toddler filing was contingent on its readout. The release shifts the filing to 2027 without mentioning the trial results.
How will cash burn drop to $41 million per quarter?
Reaching the third quarter of 2027 on $165.7 million requires a 27% cut in quarterly cash outflow by our math, even as commercial hiring continues. Management has not explained which expenses will fall if the FDA accepts the file.
When was the Warning Letter known relative to executive grants?
The board granted the chief executive performance stock units in May 2026 tied to FDA file acceptance and approval. Investors need to know whether the April Warning Letter at Fareva was known when those awards were set.